Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1994 Sep;72(3 Suppl):S24–S32. doi: 10.1136/hrt.72.3_suppl.s24

Role of ACE inhibitors in hypertension with left ventricular hypertrophy

A Mark Richards 1,2, M Gary Nicholls 1,2, Ian G Crozier 1,2
PMCID: PMC1025589  PMID: 7946799

Full text

PDF
S24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aceto J. F., Baker K. M. [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol. 1990 Mar;258(3 Pt 2):H806–H813. doi: 10.1152/ajpheart.1990.258.3.H806. [DOI] [PubMed] [Google Scholar]
  2. Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991 Apr 18;324(16):1098–1104. doi: 10.1056/NEJM199104183241605. [DOI] [PubMed] [Google Scholar]
  3. Angermann C. E., Spes C. H., Willems S., Dominiak P., Kemkes B. M., Theisen K. Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation. 1991 Aug;84(2):583–593. doi: 10.1161/01.cir.84.2.583. [DOI] [PubMed] [Google Scholar]
  4. Baker K. M., Aceto J. F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990 Aug;259(2 Pt 2):H610–H618. doi: 10.1152/ajpheart.1990.259.2.H610. [DOI] [PubMed] [Google Scholar]
  5. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Bard J. M., Bara L., Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992 Oct 15;359(6396):641–644. doi: 10.1038/359641a0. [DOI] [PubMed] [Google Scholar]
  6. Cruickshank J. M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992 Apr;6(2):85–90. [PubMed] [Google Scholar]
  7. Dahlöf B., Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens. 1992 Dec;10(12):1513–1524. doi: 10.1097/00004872-199210120-00012. [DOI] [PubMed] [Google Scholar]
  8. Dahlöf B., Pennert K., Hansson L. Regression of left ventricular hypertrophy--a meta-analysis. Clin Exp Hypertens A. 1992;14(1-2):173–180. doi: 10.3109/10641969209036180. [DOI] [PubMed] [Google Scholar]
  9. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992 Feb;5(2):95–110. doi: 10.1093/ajh/5.2.95. [DOI] [PubMed] [Google Scholar]
  10. Devereux R. B., Alonso D. R., Lutas E. M., Gottlieb G. J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57(6):450–458. doi: 10.1016/0002-9149(86)90771-x. [DOI] [PubMed] [Google Scholar]
  11. Devereux R. B., Drayer J. I., Chien S., Pickering T. G., Letcher R. L., DeYoung J. L., Sealey J. E., Laragh J. H. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 1984 Sep 1;54(6):592–595. doi: 10.1016/0002-9149(84)90255-8. [DOI] [PubMed] [Google Scholar]
  12. Devereux R. B., Lutas E. M., Casale P. N., Kligfield P., Eisenberg R. R., Hammond I. W., Miller D. H., Reis G., Alderman M. H., Laragh J. H. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984 Dec;4(6):1222–1230. doi: 10.1016/s0735-1097(84)80141-2. [DOI] [PubMed] [Google Scholar]
  13. Devereux R. B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977 Apr;55(4):613–618. doi: 10.1161/01.cir.55.4.613. [DOI] [PubMed] [Google Scholar]
  14. Dostal D. E., Baker K. M. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens. 1992 May;5(5 Pt 1):276–280. doi: 10.1093/ajh/5.5.276. [DOI] [PubMed] [Google Scholar]
  15. Drayer J. I., Gardin J. M., Weber M. A., Aronow W. S. Cardiac muscle mass during vasodilation therapy of hypertension. Clin Pharmacol Ther. 1983 Jun;33(6):727–732. doi: 10.1038/clpt.1983.99. [DOI] [PubMed] [Google Scholar]
  16. Drayer J. I., Gardin J. M., Weber M. A., Aronow W. S. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther. 1982 Sep;32(3):283–288. doi: 10.1038/clpt.1982.161. [DOI] [PubMed] [Google Scholar]
  17. Dunn F. G., McLenachan J., Isles C. G., Brown I., Dargie H. J., Lever A. F., Lorimer A. R., Murray G. D., Pringle S. D., Robertson J. W. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens. 1990 Aug;8(8):775–782. doi: 10.1097/00004872-199008000-00012. [DOI] [PubMed] [Google Scholar]
  18. Dunn F. G., Oigman W., Ventura H. O., Messerli F. H., Kobrin I., Frohlich E. D. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 1984 Jan 1;53(1):105–108. doi: 10.1016/0002-9149(84)90692-1. [DOI] [PubMed] [Google Scholar]
  19. Dussaule J. C., Michel J. B., Auzan C., Schwartz K., Corvol P., Menard J. Effect of antihypertensive treatment on the left ventricular isomyosin profile in one-clip, two kidney hypertensive rats. J Pharmacol Exp Ther. 1986 Feb;236(2):512–518. [PubMed] [Google Scholar]
  20. Egan B., Fitzpatrick M. A., Juni J., Buda A. J., Zweifler A. Importance of overweight in studies of left ventricular hypertrophy and diastolic function in mild systemic hypertension. Am J Cardiol. 1989 Oct 1;64(12):752–755. doi: 10.1016/0002-9149(89)90759-5. [DOI] [PubMed] [Google Scholar]
  21. Fouad F. M., Nakashima Y., Tarazi R. C., Salcedo E. E. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control. Am J Cardiol. 1982 Mar;49(4):795–801. doi: 10.1016/0002-9149(82)91961-0. [DOI] [PubMed] [Google Scholar]
  22. Fouad F. M., Tarazi R. C., Bravo E. L. Cardiac and haemodynamic effects of enalapril. J Hypertens Suppl. 1983 Oct;1(1):135–142. [PubMed] [Google Scholar]
  23. Freslon J. L., Giudicelli J. F. Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats. Br J Pharmacol. 1983 Nov;80(3):533–543. doi: 10.1111/j.1476-5381.1983.tb10726.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Frohlich E. D., Apstein C., Chobanian A. V., Devereux R. B., Dustan H. P., Dzau V., Fauad-Tarazi F., Horan M. J., Marcus M., Massie B. The heart in hypertension. N Engl J Med. 1992 Oct 1;327(14):998–1008. doi: 10.1056/NEJM199210013271406. [DOI] [PubMed] [Google Scholar]
  25. Grandi A. M., Venco A., Barzizza F., Petrucci E., Scalise F., Perani G., Marchesi E., Folino P., Finardi G. Double-blind comparison of perindopril and captopril in hypertension. Effects on left ventricular morphology and function. Am J Hypertens. 1991 Jun;4(6):516–520. doi: 10.1093/ajh/4.6.516. [DOI] [PubMed] [Google Scholar]
  26. Hammond I. W., Devereux R. B., Alderman M. H., Lutas E. M., Spitzer M. C., Crowley J. S., Laragh J. H. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 1986 Mar;7(3):639–650. doi: 10.1016/s0735-1097(86)80476-4. [DOI] [PubMed] [Google Scholar]
  27. Harrap S. B., Van der Merwe W. M., Griffin S. A., Macpherson F., Lever A. F. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension. 1990 Dec;16(6):603–614. doi: 10.1161/01.hyp.16.6.603. [DOI] [PubMed] [Google Scholar]
  28. Izumo S., Nadal-Ginard B., Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A. 1988 Jan;85(2):339–343. doi: 10.1073/pnas.85.2.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jalil J. E., Janicki J. S., Pick R., Weber K. T. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. Am J Hypertens. 1991 Jan;4(1 Pt 1):51–55. doi: 10.1093/ajh/4.1.51. [DOI] [PubMed] [Google Scholar]
  30. Jorgensen H., Sundsfjord J. A. The relation of plasma renin activity to left ventricular hypertrophy and retinopathy in patients with arterial hypertension. Acta Med Scand. 1974 Oct;196(4):307–313. doi: 10.1111/j.0954-6820.1974.tb01016.x. [DOI] [PubMed] [Google Scholar]
  31. Julien J., Dufloux M. A., Prasquier R., Chatellier G., Menard D., Plouin P. F., Menard J., Corvol P. Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. J Am Coll Cardiol. 1990 Jul;16(1):137–142. doi: 10.1016/0735-1097(90)90470-a. [DOI] [PubMed] [Google Scholar]
  32. Julius S., Li Y., Brant D., Krause L., Taylor D. Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension. Hypertension. 1991 Jun;17(6 Pt 2):1161–1166. doi: 10.1161/01.hyp.17.6.1161. [DOI] [PubMed] [Google Scholar]
  33. Kannel W. B., Doyle J. T., McNamara P. M., Quickenton P., Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975 Apr;51(4):606–613. doi: 10.1161/01.cir.51.4.606. [DOI] [PubMed] [Google Scholar]
  34. Kannel W. B., Gordon T., Castelli W. P., Margolis J. R. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970 Jun;72(6):813–822. doi: 10.7326/0003-4819-72-6-813. [DOI] [PubMed] [Google Scholar]
  35. Kent R. L., Hoober J. K., Cooper G., 4th Load responsiveness of protein synthesis in adult mammalian myocardium: role of cardiac deformation linked to sodium influx. Circ Res. 1989 Jan;64(1):74–85. doi: 10.1161/01.res.64.1.74. [DOI] [PubMed] [Google Scholar]
  36. Kira Y., Kochel P. J., Gordon E. E., Morgan H. E. Aortic perfusion pressure as a determinant of cardiac protein synthesis. Am J Physiol. 1984 Mar;246(3 Pt 1):C247–C258. doi: 10.1152/ajpcell.1984.246.3.C247. [DOI] [PubMed] [Google Scholar]
  37. Koren M. J., Devereux R. B., Casale P. N., Savage D. D., Laragh J. H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991 Mar 1;114(5):345–352. doi: 10.7326/0003-4819-114-5-345. [DOI] [PubMed] [Google Scholar]
  38. Kromer E. P., Elsner D., Riegger G. A. Role of neurohumoral systems for pressure induced left ventricular hypertrophy in experimental supravalvular aortic stenosis in rats. Am J Hypertens. 1991 Jun;4(6):521–524. doi: 10.1093/ajh/4.6.521. [DOI] [PubMed] [Google Scholar]
  39. Kuzuo H., Honda M., Ishinaga Y., Morioka S., Tanaka K., Kuramochi T., Mansoor A. M., Yamori Y., Moriyama K. Angiotensin converting enzyme inhibitor, captopril, inhibits cardiac hypertrophy without changing collagen types and concentration in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Apr;20(4):253–260. doi: 10.1111/j.1440-1681.1993.tb01678.x. [DOI] [PubMed] [Google Scholar]
  40. Lauer M. S., Anderson K. M., Levy D. Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1991 Nov 1;18(5):1287–1294. doi: 10.1016/0735-1097(91)90549-o. [DOI] [PubMed] [Google Scholar]
  41. Leenen F. H., Prowse S. Time-course of changes in cardiac hypertrophy and pressor mechanisms in two-kidney, one clip hypertensive rats during treatment with minoxidil, enalapril or after uninephrectomy. J Hypertens. 1987 Feb;5(1):73–83. doi: 10.1097/00004872-198702000-00011. [DOI] [PubMed] [Google Scholar]
  42. Levy D., Anderson K. M., Plehn J., Savage D. D., Christiansen J. C., Castelli W. P. Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol. 1987 Apr 1;59(8):836–840. doi: 10.1016/0002-9149(87)91102-7. [DOI] [PubMed] [Google Scholar]
  43. Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med. 1989 Jan 15;110(2):101–107. doi: 10.7326/0003-4819-110-2-101. [DOI] [PubMed] [Google Scholar]
  44. Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990 May 31;322(22):1561–1566. doi: 10.1056/NEJM199005313222203. [DOI] [PubMed] [Google Scholar]
  45. Levy D., Labib S. B., Anderson K. M., Christiansen J. C., Kannel W. B., Castelli W. P. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990 Mar;81(3):815–820. doi: 10.1161/01.cir.81.3.815. [DOI] [PubMed] [Google Scholar]
  46. Levy D., Savage D. D., Garrison R. J., Anderson K. M., Kannel W. B., Castelli W. P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987 Apr 15;59(9):956–960. doi: 10.1016/0002-9149(87)91133-7. [DOI] [PubMed] [Google Scholar]
  47. Liebson P. R. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens. 1990 Jun;3(6 Pt 1):512–517. doi: 10.1093/ajh/3.6.512. [DOI] [PubMed] [Google Scholar]
  48. Linz W., Henning R., Schölkens B. A. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. J Hypertens Suppl. 1991 Dec;9(6):S400–S401. [PubMed] [Google Scholar]
  49. Linz W., Schaper J., Wiemer G., Albus U., Schölkens B. A. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol. 1992 Dec;107(4):970–975. doi: 10.1111/j.1476-5381.1992.tb13393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Marian A. J., Yu Q. T., Workman R., Greve G., Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993 Oct 30;342(8879):1085–1086. doi: 10.1016/0140-6736(93)92064-z. [DOI] [PubMed] [Google Scholar]
  51. McLenachan J. M., Henderson E., Morris K. I., Dargie H. J. Electrocardiographic diagnosis of left ventricular hypertrophy: influence of body build. Clin Sci (Lond) 1988 Dec;75(6):589–592. doi: 10.1042/cs0750589. [DOI] [PubMed] [Google Scholar]
  52. McLenachan J. M., Henderson E., Morris K. I., Dargie H. J. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987 Sep 24;317(13):787–792. doi: 10.1056/NEJM198709243171302. [DOI] [PubMed] [Google Scholar]
  53. Meade T. W., Cooper J. A., Peart W. S. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993 Aug 26;329(9):616–619. doi: 10.1056/NEJM199308263290905. [DOI] [PubMed] [Google Scholar]
  54. Messerli F. H., Ventura H. O., Elizardi D. J., Dunn F. G., Frohlich E. D. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med. 1984 Jul;77(1):18–22. doi: 10.1016/0002-9343(84)90430-3. [DOI] [PubMed] [Google Scholar]
  55. Michel J. B. Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure. Eur Heart J. 1990 May;11 (Suppl 500):17–26. doi: 10.1093/eurheartj/11.suppl_d.17. [DOI] [PubMed] [Google Scholar]
  56. Michel J. B., Salzmann J. L., Cerol M. L., Dussaule J. C., Azizi M., Corman B., Camilleri J. P., Corvol P. Myocardial effect of converting enzyme inhibition in hypertensive and normotensive rats. Am J Med. 1988 Mar 11;84(3A):12–21. doi: 10.1016/0002-9343(88)90200-8. [DOI] [PubMed] [Google Scholar]
  57. Mooser V., Katopothis A., Casley D., Johnston C. I. Cardiac and renal hypertrophy is independent of tissue angiotensin converting enzyme and circulating angiotensin II in hypertensive rats. J Hypertens Suppl. 1991 Dec;9(6):S114–S115. [PubMed] [Google Scholar]
  58. Morgan H. E., Baker K. M. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991 Jan;83(1):13–25. doi: 10.1161/01.cir.83.1.13. [DOI] [PubMed] [Google Scholar]
  59. Nakamura F., Nagano M., Higaki J., Higashimori K., Katahira K., Morishita R., Mikami H., Ogihara T. Regression of left ventricular hypertrophy by angiotensin converting enzyme inhibitor in reduced renal mass hypertensive rats. J Hypertens Suppl. 1991 Dec;9(6):S398–S399. [PubMed] [Google Scholar]
  60. Nakashima Y., Fouad F. M., Tarazi R. C. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984 Apr 1;53(8):1044–1049. doi: 10.1016/0002-9149(84)90634-9. [DOI] [PubMed] [Google Scholar]
  61. Pauletto P., Nascimben L., Piccolo D., Secchiero S., Vescovo G., Scannapieco G., Dalla Libera L., Carraro U., Pessina A. C., Dal Palù C. Ventricular myosin and creatine-kinase isoenzymes in hypertensive rats treated with captopril. Hypertension. 1989 Nov;14(5):556–562. doi: 10.1161/01.hyp.14.5.556. [DOI] [PubMed] [Google Scholar]
  62. Pringle S. D., Macfarlane P. W., Isles C. G., Cameron H. L., Brown I. A., Lorimer A. R., Dunn F. G. Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism. J Hum Hypertens. 1988 Oct;2(3):157–159. [PubMed] [Google Scholar]
  63. Raynolds M. V., Bristow M. R., Bush E. W., Abraham W. T., Lowes B. D., Zisman L. S., Taft C. S., Perryman M. B. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30;342(8879):1073–1075. doi: 10.1016/0140-6736(93)92061-w. [DOI] [PubMed] [Google Scholar]
  64. Russell G. I., Bing R. F., Thurston H., Swales J. D. Plasma renin in hypertensive patients: significance in relation to clinical and other biochemical features. Q J Med. 1980;49(195):385–394. [PubMed] [Google Scholar]
  65. Schlant R. C., Felner J. M., Blumenstein B. A., Wollam G. L., Hall W. D., Shulman N. B., Heymsfield S. B., Gilbert C. A., Tuttle E. P. Echocardiographic documentation of regression of left ventricular hypertrophy in patients treated for essential hypertension. Eur Heart J. 1982 Apr;3 (Suppl A):171–175. doi: 10.1093/eurheartj/3.suppl_a.171. [DOI] [PubMed] [Google Scholar]
  66. Schmieder R. E., Messerli F. H., Garavaglia G. E., Nunez B. D. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 1988 Oct;78(4):951–956. doi: 10.1161/01.cir.78.4.951. [DOI] [PubMed] [Google Scholar]
  67. Schmieder R. E., Messerli F. H., Garavaglia G. E., Nunez B., MacPhee A. A., Re R. N. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med. 1988 Mar 11;84(3A):136–139. doi: 10.1016/0002-9343(88)90220-3. [DOI] [PubMed] [Google Scholar]
  68. Schmieder R. E., Messerli F. H., Sturgill D., Garavaglia G. E., Nunez B. D. Cardiac performance after reduction of myocardial hypertrophy. Am J Med. 1989 Jul;87(1):22–27. doi: 10.1016/s0002-9343(89)80478-4. [DOI] [PubMed] [Google Scholar]
  69. Schneeweiss A., Rosenthal J., Marmor A. Comparative evaluation of the acute and chronic effects of cilazapril and hydrochlorothiazide on diastolic cardiac function in hypertensive patients. J Hum Hypertens. 1990 Oct;4(5):535–539. [PubMed] [Google Scholar]
  70. Shahi M., Thom S., Poulter N., Sever P. S., Foale R. A. The effects of blood pressure reduction on abnormal left ventricular diastolic function in hypertensive patients. Eur Heart J. 1991 Sep;12(9):974–979. doi: 10.1093/eurheartj/12.9.974. [DOI] [PubMed] [Google Scholar]
  71. Sullivan J. M., Vander Zwaag R. V., el-Zeky F., Ramanathan K. B., Mirvis D. M. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol. 1993 Aug;22(2):508–513. doi: 10.1016/0735-1097(93)90057-8. [DOI] [PubMed] [Google Scholar]
  72. Suurküla M. B., Wikstrand J., Berglund G., Sivertsson R. Body weight is more important than family history of hypertension for left ventricular function. Hypertension. 1991 May;17(5):661–668. doi: 10.1161/01.hyp.17.5.661. [DOI] [PubMed] [Google Scholar]
  73. Suzuki T., Abe H., Nagata S., Saitoh F., Iwata S., Ashizawa A., Kuramochi M., Omae T. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. Am J Cardiol. 1988 Dec 1;62(17):1224–1227. doi: 10.1016/0002-9149(88)90264-0. [DOI] [PubMed] [Google Scholar]
  74. Tiret L., Kee F., Poirier O., Nicaud V., Lecerf L., Evans A., Cambou J. P., Arveiler D., Luc G., Amouyel P. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet. 1993 Apr 17;341(8851):991–992. doi: 10.1016/0140-6736(93)91075-w. [DOI] [PubMed] [Google Scholar]
  75. Trimarco B., Ricciardelli B., De Luca N., De Simone A., Cuocolo A., Galva M. D., Picotti G. B., Condorelli M. Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents. Circulation. 1985 Jul;72(1):38–46. doi: 10.1161/01.cir.72.1.38. [DOI] [PubMed] [Google Scholar]
  76. Tuzcu E. M., Golz S. J., Lever H. M., Salcedo E. E. Left ventricular hypertrophy in persons age 90 years and older. Am J Cardiol. 1989 Jan 15;63(3):237–240. doi: 10.1016/0002-9149(89)90292-0. [DOI] [PubMed] [Google Scholar]
  77. Zierhut W., Zimmer H. G., Gerdes A. M. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 1991 Sep;69(3):609–617. doi: 10.1161/01.res.69.3.609. [DOI] [PubMed] [Google Scholar]
  78. du Cailar G., Ribstein J., Grolleau R., Mimran A. Influence of sodium intake on left ventricular structure in untreated essential hypertensives. J Hypertens Suppl. 1989 Dec;7(6):S258–S259. doi: 10.1097/00004872-198900076-00125. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES